Clinical Trial Update: A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating camrelizumab plus apatinib as adjuvant therapy for hepatocellular carcinoma at high risk of recurrence after surgery or ablati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Zhujiang Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING